See-Mode Technologies, a MedTech startup based in Singapore and Australia that seeks to improve stroke prediction with Artificial Intelligence-based medical software, raised US$7m in a Series A funding.
The round was led by MassMutual Ventures Southeast Asia (MMV SEA), with participation from existing investors Blackbird Ventures, Cocoon Capital, Entrepreneur First, and SGInnovate, along with a group of angel investors.
The company intends to use the funds for its commercial expansion plans to bring its products to the Europe and United States (US) markets in the upcoming year and strengthen its existing operations and at least double its team size by hiring talent across various product roles, expanding its R&D and engineering capabilities and building up its core sales and business development team. The team is also broadening its partnerships to more research institutions around the world to build a strong base of scientific evidence for its R&D efforts.
Led by Dr Milad Mohammadzadeh, Co-Founder and Director, See-Mode Technologies applies deep learning and computational modeling techniques on medical images to help doctors predict stroke and decide on the optimal treatment for their patients. See-Mode’s first product, AVA (Augmented Vascular Analysis) is approved by Singapore’s Health Sciences Authority as a class B medical device and is now commercially available, with CE and FDA approvals pending. The company is currently running clinical studies with major stroke centers and research institutes throughout the world.